Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias

Carcinogenesis

Volumn 20, Issue 7, 1999, Pages 1225-1229

  Lemos, M C ^a   Cabrita, F J ^a   Silva, H A ^a   Vivan, M ^b   Placido F ^b   Regateiro, F J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450; GLUTATHIONE TRANSFERASE;

ARTICLE; CANCER RISK; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HEMATOLOGIC NEOPLASMS; HOMOZYGOTE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC;

EID: 0032811583     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.7.1225     Document Type: Article

References (31)

1. Nebert, D.W. (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet., 60, 265-271.
2. Weber, W.W. (1997) Pharmacogenetics. Oxford University Press, New York, NY.
3. Smith, G., Stanley, L.A., Sim, E., Strange, R.C. and Wolf, C.R. (1995) Metabolic polymorphisms and cancer susceptibility. Cancer Surv., 25, 27-65.
4. d'Errico, A., Taioli, E., Chen, X. and Vineis, P. (1996) Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers, 1, 149-173.
5. Eichelbaum, M. and Gross, A.S. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol. Ther., 46, 377-394.
6. Meyer, U.A. and Zanger, U.M. (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol., 37, 269-296.
7. Gough, A.C., Miles, J.S., Spurr, N.K., Moss, J.E., Gaedigk, A., Eichelbaum, M. and Wolf, C.R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus. Nature, 347, 773-776.
8. Daly, A.K., Brockmöller, J., Broly, F. et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193-201.
9. Sachse, C., Brockmöller, J., Bauer, S. and Roots, I. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60, 284-295.
10. Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.M., Spire, C., Lafitte, J.J., Meyer, U.A. and Broly, F. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterisation of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, 7, 193-202.
11. Mannervik, B., Awasthi, Y.C., Board, P.G. et al. (1992). Nomenclature for human glutathione transferases. Biochem. J., 282, 305-308.
12. Seidegard, J., Vorachek, W.R., Pero, R.W. and Pearson, W.R. (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl Acad. Sci. USA, 85, 7293-7297.
13. Grant, D.M. (1993) Molecular genetics of the N-acetyltransferases. Pharmacogenetics, 3, 45-50.
14. Blum, M., Grant, D.M., McBride, W., Heim, M. and Meyer, U.A. (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localisation and functional expression. DNA Cell Biol., 9, 193-203.
15. Vatsis, K.P., Weber, W.W., Bell, D.A. et al. (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics, 5, 1-17.
16. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K. and Roots, I. (1995) Arylamine N-acetylation (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet., 57, 581-592.
17. Smith, C.A.D., Smith, G. and Wolf, C.R. (1994) Genetic polymorphisms in xenobiotic metabolism. Eur. J. Cancer, 30A, 1935-1941.
18. Nebert, D.W., McKinnon, R.A. and Puga, A. (1996) Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol., 15, 273-280.
19. Arnaiz-Villena, A., Martínez-Laso, J., Gómez-Casado, E., Díaz-Campos, N., Santos, P., Martinho, A. and Breda-Coimbra, H. (1997) Relatedness among Basques, Portuguese, Spaniards, and Algerians studied by HLA allelic frequencies and haplotypes. Immunogenetics, 47, 37-43.
20. Agundez, J.A., Rodriguez, I., Olivera, M., Ladero, J.M., Garcia, M.A., Ribera, J.M. and Benitez, J. (1997) CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing, 26, 147-151.
21. Muiras, M.L., Verasdonck, P., Cottet, F. and Schächter, F. (1998) Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Hum. Genet., 102, 526-532.
22. Miller, S.A., Dykes, D.D. and Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res., 16, 1215-1218.
23. Zhong, S., Wyllie, A.H., Barnes, D., Wolf, C.R. and Spurr, N.K. (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis, 14, 1821-1824.
24. Smith, C.A.D., Wadelius, M., Gough, A.C., Harrison, D.J., Wolf, C.R. and Rane, A. (1997) A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J. Med. Genet., 34, 758-760.
25. Guengerich, F.P. (1993) Cytochrome P450 enzymes. Am. Sci., 81, 440-447.
26. Sachse, C., Brockmöller, J., Hildebrand, M., Mülller,K. and Roots, I. (1998) Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolisers of debrisoquine. Pharmacogenetics, 8, 181-185.
27. Wolf, C.R., Smith, C.A.D., Gough, A.C. et al. (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 13, 1035-1038.
28. Rostami-Hodjegan, A., Lennard, M.S., Woods, H.F. and Tucker, G.T. (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics, 8, 227-238.
29. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P.M., Bauer, S., Loddenkemper, R. and Roots, I. (1996) Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res., 56, 3961-3966.
30. Gil, J.P. and Lechner, M.C. (1998) Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygous in Portuguese patients with colorectal cancer. Carcinogenesis, 19, 37-41.
31. Ratain, M.J. (1997) Pharmacology of cancer chemotherapy. In DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds) Cancer: Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, PA, pp. 375-385.